CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于外泌体的纳米颗粒与癌症免疫治疗
英文原题：Exosome-based nanoparticles and cancer immunotherapy.
查看英文原题
Exosome-based nanoparticles and cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在过去几十年中，癌症免疫治疗面临免疫原性、低效性和细胞毒性等挑战。因此，基于外泌体的癌症免疫治疗作为一种有前景的替代方案迅速获得关注。外泌体是一种大小在50至150 nm之间的细胞外囊泡（EVs），具有自体来源特性，且与传统疗法相比副作用更少。基于外泌体的免疫治疗涵盖三个重要领域：癌症疫苗、共抑制检查点和过继性T细胞治疗。每个领域都利用外泌体的固有优势，在个体化肿瘤治疗和精准医学方面展现出巨大潜力。本综述旨在通过考察外泌体基纳米颗粒的特性并总结癌症免疫治疗的最新研究进展，阐明其作为癌症疗法具有前景的原因。
展开英文摘要原文
Over the past decades, cancer immunotherapy has encountered challenges such as immunogenicity, inefficiency, and cytotoxicity. Consequently, exosome-based cancer immunotherapy has gained rapid traction as a promising alternative. Exosomes, a type of extracellular vesicles (EVs) ranging from 50 to 150 nm, are self-originating and exhibit fewer side effects compared to traditional therapies.
Exosome-based immunotherapy encompasses three significant areas: cancer vaccination, co-inhibitory checkpoints, and adoptive T-cell therapy. Each of these fields leverages the inherent advantages of exosomes, demonstrating substantial potential for individualized tumor therapy and precision medicine. This review aims to elucidate the reasons behind the promise of exosome-based nanoparticles as cancer therapies by examining their characteristics and summarizing the latest research advancements in cancer immunotherapy.
论文信息
- 作者
- Ye J、Li D、Jie Y、Luo H、Zhang W、Qiu C
- 第一作者单位
- Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Jiangxi Province, 330000 China. Electronic address: 971358324@qq.com.China
- 通讯作者单位
- Gastrointestinal Surgery, Pingxiang People's Hospital, Jiangxi Province 330000, China. Electronic address: 17826938900@163.com.China
- 文献类型
- 综述
- 期刊
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2024 Oct
- 原文标识
- PubMed 39167842 · DOI 10.1016/j.biopha.2024.117296